Skip to content
Clinical Trials – home
PolandBack to Poland

Clinical trials in Katowice – page 12

736 clinical trials in Katowice, Poland across 18 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

PolandOur site in PolandBadaniaKliniczne.pl(opens in a new tab)
Katowice at a glance
736
clinical trials
  • Research sites18
Type of trial
Recruitment status
Quick filters

736 trials in Katowice

Open in trial search

A study to evaluate the safety and effectiveness of empasiprubart and efgartigimod alfa in patients with generalized myasthenia gravis.

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

A study of IM-101 in adults with generalized myasthenia gravis or ocular myasthenia gravis

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:IM-101
  • Sponsor:Immunabs Inc.

Dyslipidaemia+1

Recruiting

Study of the efficacy and safety of inclisiran and a drug combination in patients with acute coronary syndrome

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Atorvastatin
  • Sponsor:Novartis Pharma AG

A study to evaluate the safety and effectiveness of BNT324 and BNT327 in patients with advanced lung cancer

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:BNT327
  • Sponsor:BioNTech SE

N1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Ly3437943 Sodium
  • Sponsor:Eli Lilly & Co.

Study of ublituximab compared to fingolimod for children and teenagers aged 10 to 17 years with relapsing multiple sclerosis

Registered drug
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Fingolimod
  • Sponsor:Tg Therapeutics Inc.

A study testing the safety and effectiveness of BP1.

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:N-[4-[2-[4-(3-Cyanophenyl)Piperazin-1-Yl]Ethyl]Cyclohexyl]-3-Methoxypropanamide
  • Sponsor:Bioprojet Pharma

Cardiac failure+1

Recruiting

A study of finerenone with standard treatment for children and young adults from birth to 18 years with heart failure and left ventricular systolic dysfunction

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years
  • Substances:Finerenone
  • Sponsor:Bayer AG

Cardiac failure+1

Recruiting

A study of finerenone added to standard treatment in children aged 6 months to under 18 years with heart failure and reduced left heart pumping function

Investigational
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Finerenone
  • Sponsor:Bayer AG

A study comparing furazidin and clindamycin for women with bacterial vaginosis

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Clindamycin Phosphate
  • Sponsor:Adamed Pharma S.A.

A study of bleximenib combined with intensive chemotherapy for adults with newly diagnosed acute myeloid leukemia with specific genetic changes.

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:BLEXIMENIB
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

A study comparing prasinezumab with placebo for people with early-stage Parkinson's disease

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Prasinezumab
  • Sponsor:F. Hoffmann-La Roche AG

Other cities in Poland

The busiest research cities in the country

All 239 cities in Poland

Clinical research in Katowice

What the registry says about research in the country

01 Respiratory Conditions

Research focusing on respiratory health conditions, including studies on RSV infections in older adults and treatments for chronic obstructive pulmonary disease. Current trials are evaluating new vaccines and investigating innovative therapies for chronic rhinosinusitis.

  • RSV Vaccine Studies
  • COPD Treatment Evaluation
  • Chronic Rhinosinusitis Management
02 Neurological Disorders

Innovative research into neurodegenerative conditions, with a particular focus on Parkinson's disease treatments. Studies are examining new therapeutic approaches and investigating targeted treatments for early-stage Parkinson's.

  • Early Parkinson's Disease Interventions
  • LRRK2-Driven Parkinson's Research
  • Generalized Myasthenia Gravis Treatment
03 Dermatological Conditions

Comprehensive studies on inflammatory skin conditions, including trials for moderate to severe plaque psoriasis, genital psoriasis, and atopic dermatitis. Research focuses on evaluating new biological treatments and innovative therapies.

  • Plaque Psoriasis Treatments
  • Atopic Dermatitis Management
  • Novel Therapeutic Approaches
04 Oncology and Hematology

Advanced research in cancer treatment, particularly focusing on blood cancers and prostate cancer. Studies include innovative approaches for treating diffuse large B-cell lymphoma and acute myeloid leukemia.

  • Lymphoma Therapies
  • Leukemia Treatments
  • Prostate Cancer Management
05 Autoimmune Conditions

Research investigating treatments for various autoimmune disorders, including Sjögren's Syndrome and chronic inflammatory demyelinating polyneuropathy. Studies focus on evaluating new therapeutic agents and their long-term effectiveness.

  • Sjögren's Disease Therapies
  • CIDP Treatment Approaches
  • Inflammatory Disease Management
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.